Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity
US11992493B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2022 |
| Grant date | May 28, 2024 |
| Priority date | — |
| Expiry date | Dec 16, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A use of a compound or a medicinal derivative thereof in inhibiting calcium/calmodulin-dependent protein kinase type II gamma (CaMK2γ) protein activity is provided, and belongs to the technical field of protein inhibitors. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe, and stable. Moreover, the compound has a strong binding force with human-derived CaMK2γ protein and mouse-derived CaMK2γ protein, and binding constants are KD=2.54×10−5M and KD=6.84×10−5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.